Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBA University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes.
Study reveals potential to reverse lung fibrosis using the body's …
WEBApr 12, 2024 · Researchers are urgently trying to find ways to prevent or slow idiopathic pulmonary fibrosis (IPF) and related lung conditions, which can cause worsening shortness of breath, dry cough, and...
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with …
Experimental anticancer drug shows promise as treatment for Idiopathic …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
Researchers identify new molecular target for idiopathic pulmonary ...
WEBMar 10, 2021 · Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. IPF is characterized by severe scarring of the lungs, a condition called fibrosis, which makes it progressively difficult to breathe.
Pulmonary Fibrosis Foundation Unveils Groundbreaking …
WEBJan 22, 2024 · Dr. Berhan investigates idiopathic pulmonary fibrosis (IPF) using a unique three-dimensional organoid model. Analyzing genetic information at the individual cell level, he aims to unravel mechanisms controlling changes in lung cells, with the goal of discovering new pathways and potential drug targets for IPF treatment.
Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis …
WEBSep 16, 2024 · IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind ...
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic ...
WEBMay 15, 2022 · Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis. In this phase 2,...
Insilico Medicine reports positive Phase IIa | EurekAlert!
WEBSep 18, 2024 · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. Positive results ...